Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Boston Scientific Acurate neo2 TAVR

Boston Scientific's new TAVR system associated with high success rate, low mortality rate

The new-look device gained CE mark approval in Europe in 2020, but it has not been approved yet in the United States.

Thumbnail

Socioeconomic status and mental health make a big impact on AVR outcomes

Nontraditional risk factors such as dementia, PTSD, bipolar disorder and low socioeconomic status are all important to consider when patients are candidates for aortic valve replacement. 

Anteris Technologies duravr heart valve

Regulatory Roundup: Updates on Medtronic and LivaNova recalls, FDA-cleared AI models, a new heart valve and more

Read our recap of some of the biggest FDA-related stories that impacted cardiology in the last month.

Medtronic launches Evolut FX TAVR system aortic stenosis

Medtronic’s newest self-expanding TAVR system linked to improved performance

Medtronic presented the real-world data at the PCR London Valves 2022 conference. The company's Evolut FX TAVR system gained FDA approval back in August 2021. 

Edwards Lifesciences Corporation has shared new one-year data on the safety and effectiveness of its Evoque transcatheter tricuspid valve replacement (TTVR) system among patients with tricuspid regurgitation (TR)

Edwards shares new one-year data on transcatheter tricuspid valve replacement

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates. 

Brian Lindman, MD, MSCI, medical director of the Structural Heart and Valve Center and an associate professor of medicine, Vanderbilt University Medical Center, explains the new American Heart Association (AHA) Target Aortic Stenosis (AS) program. It was announced at the AHA 2022 meeting and is designed to help screen with echo to find more AS patients.

VIDEO: AHA says aortic stenosis is undertreated and underdiagnosed

Brian Lindman, MD, medical director of the Structural Heart and Valve Center, Vanderbilt University Medical Center, explains the new American Heart Association (AHA) Target Aortic Stenosis (AS) program to screen with echo to find more AS patients. 

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

Predictors of 1-year mortality after TAVR are significantly different among men and women

Atrial fibrillation and peripheral artery disease, for example, are both predictors of mortality among women, but not men. 

A team of cardiologists and cardiac surgeons in Hong Kong has performed the first successful undermining iatrogenic coronary obstruction with radiofrequency needle procedure—or UNICORN for short—on a high-risk valve-in-valve transcatheter aortic valve replacement (TAVR) patient. The group wrote about their experience in Circulation: Cardiovascular Interventions, a journal launched and distributed by the American Heart Association.

Cardiologists make history, perform first UNICORN procedure during valve-in-valve TAVR

BASILICA was considered for the 67-year-old female patient, but UNICORN was seen as an overall better option. The full case study was published in Circulation: Cardiovascular Interventions.